Antiseizure medication (ASM) efficacy assessment based on change in seizure frequency (SF) is influenced by intrinsic seizure variability, especially at low SFs; Low SFs exclude patients from trials, and prolong observation periods, limiting the development of new drugs and delaying therapeutic decisions; Electroencephalogram (EEG) signal dimension (DIM) is a reliable SF-independent measure of seizure susceptibility and therapeutic response to ASMs; DIM is a robust alternative to SF for ASM...